Allergan Inc., maker of the wrinkle smoother Botox, said third-quarter profit rose 8.2% on higher sales of eye and skin-care treatments.
Net income increased to $179 million, or 58 cents a share, from $165.4 million, or 54 cents, a year earlier, the Irvine company said. Profit excluding one-time items was 70 cents a share, beating by 1 cent the average estimate of analysts surveyed by Bloomberg.
Revenue rose for many drugs including Botox, countering a decline seen earlier this year as consumers cut discretionary spending in the recession.
Allergan shares rose $1.37, or 2.6%, to $54.92.